319 related articles for article (PubMed ID: 15313915)
1. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.
Nishizaki M; Sasaki J; Fang B; Atkinson EN; Minna JD; Roth JA; Ji L
Cancer Res; 2004 Aug; 64(16):5745-52. PubMed ID: 15313915
[TBL] [Abstract][Full Text] [Related]
2. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
4. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
Garinis GA; Gorgoulis VG; Mariatos G; Zacharatos P; Kotsinas A; Liloglou T; Foukas P; Kanavaros P; Kastrinakis NG; Vassilakopoulos T; Vogiatzi T; Field JK; Kittas C
J Pathol; 2001 Jan; 193(1):55-65. PubMed ID: 11169516
[TBL] [Abstract][Full Text] [Related]
5. Fhit, a tumor suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim H; Kim CH
Oncotarget; 2017 May; 8(19):31923-31937. PubMed ID: 28404875
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression.
Ji L; Fang B; Yen N; Fong K; Minna JD; Roth JA
Cancer Res; 1999 Jul; 59(14):3333-9. PubMed ID: 10416589
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L
Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283
[TBL] [Abstract][Full Text] [Related]
8. The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells.
Zandi R; Xu K; Poulsen HS; Roth JA; Ji L
Cancer Invest; 2011 Dec; 29(10):683-91. PubMed ID: 22085272
[TBL] [Abstract][Full Text] [Related]
9. Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer.
Zhang YF; Zhang BC; Zhang AR; Wu TT; Liu J; Yu LF; Wang WX; Gao JF; Fang DC; Rao ZG
Oncol Rep; 2013 Oct; 30(4):1989-95. PubMed ID: 23933826
[TBL] [Abstract][Full Text] [Related]
10. Aloperine in combination with therapeutic adenoviral vector synergistically suppressed the growth of non-small cell lung cancer.
Muhammad T; Sakhawat A; Khan AA; Huang H; Khan HR; Huang Y; Wang J
J Cancer Res Clin Oncol; 2020 Apr; 146(4):861-874. PubMed ID: 32088783
[TBL] [Abstract][Full Text] [Related]
11. Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line.
Cavazzoni A; Galetti M; Fumarola C; Alfieri RR; Roz L; Andriani F; Carbognani P; Rusca M; Sozzi G; Petronini PG
Cancer Lett; 2007 Feb; 246(1-2):69-81. PubMed ID: 16616810
[TBL] [Abstract][Full Text] [Related]
12. Involvement of FHIT in lung carcinogenesis prospects for future clinical gene therapy applications.
Sozzi G; Andriani F; Gramegna M; Roz L
Suppl Tumori; 2002; 1(4):S62. PubMed ID: 12415825
[No Abstract] [Full Text] [Related]
13. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.
Gorgoulis VG; Zacharatos P; Kotsinas A; Liloglou T; Kyroudi A; Veslemes M; Rassidakis A; Halazonetis TD; Field JK; Kittas C
Am J Pathol; 1998 Dec; 153(6):1749-65. PubMed ID: 9846966
[TBL] [Abstract][Full Text] [Related]
14. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo.
Nishizaki M; Meyn RE; Levy LB; Atkinson EN; White RA; Roth JA; Ji L
Clin Cancer Res; 2001 Sep; 7(9):2887-97. PubMed ID: 11555607
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of both FHIT and p53 cooperate in deregulating proliferation-related pathways in lung cancer.
Andriani F; Roz E; Caserini R; Conte D; Pastorino U; Sozzi G; Roz L
J Thorac Oncol; 2012 Apr; 7(4):631-42. PubMed ID: 22425911
[TBL] [Abstract][Full Text] [Related]
16. Loss of FHIT function in lung cancer and preinvasive bronchial lesions.
Sozzi G; Pastorino U; Moiraghi L; Tagliabue E; Pezzella F; Ghirelli C; Tornielli S; Sard L; Huebner K; Pierotti MA; Croce CM; Pilotti S
Cancer Res; 1998 Nov; 58(22):5032-7. PubMed ID: 9823304
[TBL] [Abstract][Full Text] [Related]
17. Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2.
Bougeret C; Virone-Oddos A; Adeline E; Lacroix F; Lefranc C; Ferrero L; Huet T
Cancer Gene Ther; 2000 May; 7(5):789-98. PubMed ID: 10830726
[TBL] [Abstract][Full Text] [Related]
18. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
[TBL] [Abstract][Full Text] [Related]
20. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells.
Ishii H; Dumon KR; Vecchione A; Trapasso F; Mimori K; Alder H; Mori M; Sozzi G; Baffa R; Huebner K; Croce CM
Cancer Res; 2001 Feb; 61(4):1578-84. PubMed ID: 11245468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
